China's huge and increasingly elderly population, some remotely situated in rural areas, will be provided with strong healthcare infrastructure, states a new report by healthcare experts GBI Research.
The rising incidence of chronic and infectious diseases in this vast country serves to benefit both patients and medical device companies, who may supply China's government to meet their new healthcare reforms.
The healthcare reform initiative known as ‘Opinions on Deepening the Health Care System Reform', or the ‘New Health Care Reform Plan', is being implemented by the Chinese State Council and the Communist Party of China (CPC) Central Committee, and represents a major driving factor for the healthcare sector in China. The reforms aim to provide health services for both the urban and rural population.
Healthcare infrastructure improvements are expected to drive market growth for both international and domestic companies, due to improved affordability and accessibility to healthcare services within a growing number of hospitals. New insurance policies aiming to increase the reimbursement ratio for a number of diseases will also lead to an expanding patient base.
Chronic diseases go hand in hand with elderly populations and demand significant medical support. An increasing life expectancy is leading to a growing incidence of ophthalmic diseases, as the elderly population has a high percentage of patients suffering from cataracts, with a large number of cases being added annually. Despite the large patient pool, China displays a low Cataract Surgery Rate (CSR), due to high costs, limited public awareness, and a lack of facilities in rural areas. However, the implementation of government-backed insurance schemes will increase reimbursement for medical treatment, and a significant demand is expected to be seen for ophthalmic surgery devices.
Infectious diseases can also become more common in developing countries, as populations become more urbanized and live in closer quarters to one another. China's medical devices market is dominated by In Vitro Diagnostics (IVD) and driven by a large patient pool that requires large volumes of tests - especially amidst rising cases of infectious diseases, which claimed nearly 15,802 lives in 2011. Improving the affordability of IVD products in China through new healthcare reforms is expected to boost the market.
Rapid urbanization and economic development has also resulted in lifestyle and nutritional changes, which have caused an increase in the incidence of conditions such as diabetes and cardiovascular diseases, which require diagnostic testing and monitoring.
The medical devices market in China is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11%, from $14.3 billion in 2011 to reach $30.4 billion in 2018.
This report provides key data, information and analysis on the medical devices market in China, giving market landscape, competitive landscape and market trends information on ten medical devices markets: ophthalmic devices, In Vitro Diagnostics (IVD), diagnostic imaging, cardiovascular devices, nephrology and urology devices, orthopedic devices, drug delivery devices, diabetes care devices, wound care management, and healthcare IT. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. It also reviews the competitive landscape, gives a detailed analysis of the pipeline products in each market, and reviews details regarding important merger and acquisition deals.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.